ATE189816T1 - Neue imidazolinderivate mit imidazolin-rezeptor affinität - Google Patents

Neue imidazolinderivate mit imidazolin-rezeptor affinität

Info

Publication number: ATE189816T1
Authority: AT; Austria
Prior art keywords: halo; imidazoline; phenyl; new; alkyl
Prior art date: 1996-12-04

Application number

AT97402891T

Other languages

English (en)

Inventor

Marc Payard

Saadia Danoun

Genevieve Baziard-Mouysset

Maria Anastassiadou

Daniel-Henri Caignard

Pierre Renard

Dominique Manechez

Elizabeth Scalbert

Marie-Claire Rettori

Original Assignee

Adir

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-04

Filing date

1997-12-02

Publication date

2000-03-15

1997-12-02 Application filed by Adir filed Critical Adir

2000-03-15 Application granted granted Critical

2000-03-15 Publication of ATE189816T1 publication Critical patent/ATE189816T1/de

Links

150000002462 imidazolines Chemical class 0.000 title abstract 2
229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 title abstract 2
102000009032 Imidazoline Receptors Human genes 0.000 title 1
108010049134 Imidazoline Receptors Proteins 0.000 title 1
125000001475 halogen functional group Chemical group 0.000 abstract 8
125000000217 alkyl group Chemical group 0.000 abstract 4
-1 1-phenyl-1-cyclohexylmethyl Chemical group 0.000 abstract 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
125000004442 acylamino group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 abstract 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

AT97402891T 1996-12-04 1997-12-02 Neue imidazolinderivate mit imidazolin-rezeptor affinität ATE189816T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9614844A FR2756560A1 (fr)	1996-12-04	1996-12-04	Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
ATE189816T1 true ATE189816T1 (de)	2000-03-15

Family

ID=9498304

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97402891T ATE189816T1 (de)	1996-12-04	1997-12-02	Neue imidazolinderivate mit imidazolin-rezeptor affinität

Country Status (18)

Country	Link
US (1)	US5925665A (de)
EP (1)	EP0846688B1 (de)
JP (1)	JPH10168065A (de)
CN (1)	CN1091443C (de)
AT (1)	ATE189816T1 (de)
BR (1)	BR9706126A (de)
CA (1)	CA2223541A1 (de)
DE (1)	DE69701307T2 (de)
DK (1)	DK0846688T3 (de)
ES (1)	ES2145563T3 (de)
FR (1)	FR2756560A1 (de)
GR (1)	GR3032715T3 (de)
HU (1)	HUP9702341A3 (de)
NO (1)	NO309602B1 (de)
NZ (1)	NZ329312A (de)
PL (1)	PL323515A1 (de)
PT (1)	PT846688E (de)
ZA (1)	ZA9710918B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2201699A (en) *	1997-12-19	1999-07-12	Eli Lilly And Company	Hypoglycemic imidazoline compounds
EP1266897A3 (de) *	1997-12-19	2003-12-03	Eli Lilly And Company	Hypoglykämische Imidazolinderivate
FR2787451B1 (fr) *	1998-12-18	2001-01-26	Adir	Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2351082A (en) *	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Synthesis of Cyclic Substituted Amidines
GB2351081A (en) *	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
GB9914255D0 (en) *	1999-06-18	1999-08-18	Lilly Forschung Gmbh	Pharmaceutical compounds
US20040009976A1 (en) *	2002-04-30	2004-01-15	Kumiko Takeuchi	Hypoglycemic imidazoline compounds
EP1517688A2 (de)	2002-06-19	2005-03-30	Solvay Pharmaceuticals GmbH	Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
DE10315640A1 (de) *	2003-04-04	2004-10-14	Ignatov, Konstantin	Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung
EP1753727B1 (de) *	2004-05-18	2008-11-19	F.Hoffmann-La Roche Ag	Neuartige cis-imidazoline
CN103275011A (zh) *	2013-06-13	2013-09-04	南京工业大学	咪唑烷类杂环的新合成方法
KR20160042039A (ko)	2013-08-09	2016-04-18	알데릭스, 인코포레이티드	인산염 수송을 억제하기 위한 화합물 및 방법
CN112624975A (zh) *	2020-11-27	2021-04-09	华南农业大学	一种妥拉唑林半抗原、人工抗原、抗体及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4140859A (en) *	1974-11-04	1979-02-20	Sandoz, Inc.	Dilithiated 2-(o-tolyl)-2-imidazolines
DE2854428A1 (de) *	1978-12-16	1980-06-26	Basf Ag	Verfahren zur herstellung von 2-imidazolinen
US4910206A (en) *	1986-07-14	1990-03-20	Sandoz Pharmaceuticals Corp.	5-hetero-or aryl-substituted-imidazo(2,1-a)isoquinolines and their use as PAF receptor antagonists
JP2545646B2 (ja) *	1990-11-22	1996-10-23	松下電器産業株式会社	非線形光学材料
US5574059A (en) *	1995-10-27	1996-11-12	Cornell Research Foundation, Inc.	Treating disorders mediated by vascular smooth muscle cell proliferation

1996
- 1996-12-04 FR FR9614844A patent/FR2756560A1/fr not_active Withdrawn
1997
- 1997-12-01 JP JP9330116A patent/JPH10168065A/ja active Pending
- 1997-12-02 AT AT97402891T patent/ATE189816T1/de not_active IP Right Cessation
- 1997-12-02 DK DK97402891T patent/DK0846688T3/da active
- 1997-12-02 DE DE69701307T patent/DE69701307T2/de not_active Expired - Fee Related
- 1997-12-02 ES ES97402891T patent/ES2145563T3/es not_active Expired - Lifetime
- 1997-12-02 CA CA002223541A patent/CA2223541A1/fr not_active Abandoned
- 1997-12-02 PT PT97402891T patent/PT846688E/pt unknown
- 1997-12-02 EP EP97402891A patent/EP0846688B1/de not_active Expired - Lifetime
- 1997-12-03 CN CN97125774A patent/CN1091443C/zh not_active Expired - Fee Related
- 1997-12-03 BR BR9706126A patent/BR9706126A/pt unknown
- 1997-12-03 US US08/984,673 patent/US5925665A/en not_active Expired - Fee Related
- 1997-12-03 NZ NZ329312A patent/NZ329312A/en unknown
- 1997-12-03 HU HU9702341A patent/HUP9702341A3/hu unknown
- 1997-12-03 NO NO975591A patent/NO309602B1/no unknown
- 1997-12-04 ZA ZA9710918A patent/ZA9710918B/xx unknown
- 1997-12-04 PL PL97323515A patent/PL323515A1/xx unknown
2000
- 2000-02-21 GR GR20000400414T patent/GR3032715T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
FR2756560A1 (fr)	1998-06-05
US5925665A (en)	1999-07-20
AU719145B2 (en)	2000-05-04
DE69701307T2 (de)	2000-09-14
NZ329312A (en)	1998-07-28
EP0846688B1 (de)	2000-02-16
ZA9710918B (en)	1998-06-15
GR3032715T3 (en)	2000-06-30
CA2223541A1 (fr)	1998-06-04
HUP9702341A3 (en)	1999-04-28
DK0846688T3 (da)	2000-07-17
HUP9702341A2 (hu)	1998-07-28
PT846688E (pt)	2000-05-31
CN1091443C (zh)	2002-09-25
PL323515A1 (en)	1998-06-08
JPH10168065A (ja)	1998-06-23
NO309602B1 (no)	2001-02-26
BR9706126A (pt)	1999-05-18
HK1011207A1 (en)	1999-07-09
NO975591L (no)	1998-06-05
NO975591D0 (no)	1997-12-03
AU4765297A (en)	1998-06-11
HU9702341D0 (en)	1998-03-02
CN1186074A (zh)	1998-07-01
DE69701307D1 (de)	2000-03-23
ES2145563T3 (es)	2000-07-01
EP0846688A1 (de)	1998-06-10

Legal Events

Date	Code	Title	Description
2000-08-15	UEP	Publication of translation of european patent specification
2004-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69701307D1 (de)	2000-03-23	Neue Imidazolinderivate mit Imidazolin-Rezeptor Affinität
DK0771197T3 (da)	2003-06-23	Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
BG104670A (en)	2001-05-31	4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists
JP2004521924A5 (de)	2005-12-22
NO883487D0 (no)	1988-08-05	Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
ZA934997B (en)	1995-01-12	Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives
DE3682032D1 (de)	1991-11-21	Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide.
ES2160649T3 (es)	2001-11-16	Nuevos compuestos lactamicos y procedimientos para su preparacion.
NO954139D0 (no)	1995-10-18	Kinoksaliner, deres fremstilling og anvendelse
SE8303987L (sv)	1984-01-16	N-fenylpyrazolderivat anvendbara som herbicider
HU9503592D0 (en)	1996-02-28	Use of 5-acyl-1,4-dihydropyridines
AU528634B2 (en)	1983-05-05	Pyrimido- and imidazo-pyroindole derivatives
FI962768A0 (fi)	1996-07-05	N-(2-ftaali-imidoetyyli)substituoituja transpiperidiini-2,5-dikarboksylaatteja
ATE178052T1 (de)	1999-04-15	Alkyl-5-methylsulfonyl-benzoyl-guanidin-derivat
DE59607988D1 (de)	2001-11-29	Substituierte Trifluormethylpyridine verwendbar als Zwischenprodukte für herbizide 1-(Pyridyl)-Pyrazole
MX9304574A (es)	1994-02-28	Nuevas sulfonilureas.
FI853470A0 (fi)	1985-09-11	Foerfarande foer framstaellning av saosom antimikrobiella aemnen anvaendbara n-/1-alkyl- eller arylmetyl)-4 (1h)pyridinylidin/alkanaminer.
TW429147B (en)	2001-04-11	Pharmaceutical composition for the treatment of CNS disorders
DK0591236T3 (da)	1997-03-17	Fremgangsmåde til fremstilling af 5-(3-butyryl-2,4,6-trimethyl)-2-(1-(ethoxyimino)propyl)-3-hydroxycyklohex-2-en-1-on